US Treasury Hints at $1 Trillion Bond Injection, KOSDAQ Anticipated to Recover 1,000 Level

With news of the US Treasury hinting at a $1 trillion fund injection into the bond market, there is an outlook that the KOSDAQ market has ample time to recover the 1,000-point level. Such measures are expected to positively impact interest rate concerns and debt resolution. Therefore, it has been analyzed that rather than an inverse strategy betting on a market decline, it is important to maintain a positive outlook for the market in the second half and plan investments.

Manager Choi Won-beom optimistically assessed the overall market trend, emphasizing a high probability of the stock market rising. He added that the US Treasury's large-scale fund injection will contribute to market stabilization, acting as an additional driving force for the KOSDAQ index's further ascent.

LNF, a leading secondary battery stock, surged 16% intraday with institutional buying, and EcoPro is also forming a pattern of rising after confirming its bottom. This trend is reigniting investor interest in the secondary battery sector.

Manager Choi Won-beom emphasized the need to closely monitor the future trends of the secondary battery and bio sectors. Both sectors are likely to play a significant role amid market volatility, and a cautious approach to stocks that have confirmed their bottom is necessary.

The US Treasury has hinted at the possibility of injecting $1 trillion into the bond market. This is interpreted as a preemptive measure to address interest rate concerns and national debt issues. Such a large-scale fund injection is expected to significantly contribute to market stabilization.

Manager Choi Won-beom stated that this announcement could amplify volatility in the futures market, and geopolitical variables such as future sanctions against Iran could have additional impacts. The market is expected to monitor the US Treasury's actions, seeking clues to resolve interest rate and debt issues.

Samsung Electronics is facing limits on treasury stock buybacks due to the 10% rule of the financial industry act. While it aims to proceed with treasury stock buybacks as part of its 110 trillion won shareholder return policy, the combined stake of Samsung Life and Samsung Fire & Marine Insurance is nearing 10%, making further treasury stock purchases and buybacks difficult. This has been analyzed as a factor behind the sharp decline in Samsung Electronics' common shares.

In this situation, the possibility of an alternative ownership structure through the inflow of preferred stock buying is being raised. It seems the company is exploring ways to continue its shareholder return policy without being affected by the financial industry act by utilizing non-voting preferred shares.

This issue significantly impacts Samsung Electronics' governance structure and shareholder return policy, and market attention is expected to focus on Samsung Electronics' future response.

An outlook suggests that Samsung Electronics may consider repurchasing non-voting preferred shares to circumvent the financial industry act's 10% rule. Since preferred shares do not have voting rights, they are excluded from the financial industry act's calculation, which could resolve the issue of limitations on treasury stock buybacks.

This strategy is being discussed as an alternative to enhance shareholder value without being subject to the financial industry act's regulations, by utilizing treasury stock buyback funds to expand preferred share purchases and buybacks.

The selling by foreign and institutional investors in Samsung Electronics is interpreted as a recurring phenomenon, and an analysis suggests that such selling does not imply a decline in Samsung Electronics' intrinsic value. Therefore, the opinion was put forward that there is no reason to sell from a short-term trading perspective at this juncture.

Manager Choi Won-beom emphasized that Samsung Electronics remains a promising investment for the long term, advising investors to expect returns through long-term holding rather than reacting to short-term stock price fluctuations.

The US government has officially requested Korea's participation in acquiring a stake in Westinghouse, formalizing the formation of 'Team Chorus'. This is part of the US's announced project to build 10 nuclear power plants, with discussions underway for KEPCO and KEPCO E&C's equity participation.

This cooperation is analyzed as an effort to complement the US's shortage in large nuclear power plant construction capabilities with Korea's technology. Attention is focused on whether Korea and the US can create synergy in the nuclear power sector.

Although concerns about overvalued acquisition risk were raised, citing Toshiba's past failed acquisition of Westinghouse, a rebuttal has also emerged. The argument is that the current situation is much different from the past due to business diversification, including SMRs (Small Modular Reactors).

Manager Choi Won-beom pointed out that it is difficult to evaluate current cooperation based solely on past failures and explained that when considering various nuclear power business areas, the risk of overvalued acquisition is somewhat exaggerated.

Four nuclear-related companies—KEPCO E&C, Doosan Enerbility, BH, and Woori Technology—have been selected as target stocks for tomorrow. These stocks are analyzed to have a high probability of attracting demand, along with expectations for growth in the nuclear power industry. In particular, KEPCO E&C is expected to benefit from Korea-US cooperation based on its nuclear power technology.

Doosan Enerbility represents Doosan Group's capabilities in the nuclear power business, while BH and Woori Technology are also gaining attention as companies providing nuclear-related components and services. However, it was suggested that Tae-Woong, being largely plant-oriented, should be considered for its overlap with Doosan Enerbility.

Hanmi Pharmaceutical successfully exported 3 trillion won worth of technology to Genentech, a subsidiary of Roche in the US, and recorded a surge to the upper limit. The upfront payment alone for this contract amounts to 290 billion won, exceeding Hanmi Pharmaceutical's R&D investment of 230 billion won. This significantly improved Hanmi Pharmaceutical's financial situation.

The exported technology is an obesity treatment that prevents muscle loss, evaluated to have differentiated competitiveness from existing obesity treatments. This contract demonstrates Hanmi Pharmaceutical's technological prowess being recognized in the global market, raising expectations for future growth.

InBody is gaining attention by entering the obesity treatment market. Having entered GLP-1 related business, InBody boasts a unique database based on body composition measurement data. Manager Choi Won-beom cited InBody's enormous database as its biggest advantage, predicting it will secure differentiated competitiveness in the obesity treatment market.

InBody boasts excellent profitability, with operating profit growing 70% year-on-year and quarterly growth also recording 36%. Especially noteworthy is an operating profit margin of 24%, and these financial achievements are expected to create synergy with its entry into the obesity treatment market.

Finger is drawing market attention with various materials such as stablecoins and AI physical robotics. Manager Choi Won-beom evaluated Finger as having sustainable growth drivers that can lead the September market, not just a temporary theme.

Finger is strengthening its technological capabilities by acquiring Mikaelo Robotics, a robot and AI technology company, and is also pursuing stablecoin and STO (Security Token Offering) related businesses. US bond market instability and movements toward digital asset legalization are expected to positively impact Finger's growth.

An outlook suggests that the upward momentum of large semiconductor stocks like Samsung Electronics and SK Hynix will slow down. Doubts among individual investors regarding these large-cap stocks are growing, and an analysis indicates that major players may utilize this sentiment to shift funds to the KOSDAQ market.

Manager Choi Won-beom emphasized that a KOSDAQ-centered rotational market will unfold after September, advising attention to KOSDAQ stocks with individual themes and growth potential rather than large-cap stocks.